Sharekhan

Divi's Laboratories Ltd

Thu 13/11/2025,12:19:57 NSE: DIVISLAB

₹ 6564.50 44.50 (0.68%)
BUY NOW Buy Divi's Laboratories Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Divi's Laboratories Ltd

Thu 13/11/2025,12:23:0

Divi's Laboratories Ltd

Thu 13/11/2025,12:19:57 | NSE : DIVISLAB

₹ 6564.5044.50 (0.68%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 6525.50

Previous Close

₹ 6520.00

Volume

218337

Mkt Cap ( Rs. Cr)

₹174266.85

High

₹ 6576.50

Low

₹ 6473.00

52 Week High

₹ 7071.50

52 Week Low

₹ 4955.00

Book Value Per Share

₹ 563.87

Dividend Yield

0.45

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Divi's Laboratories Ltd

Your Vote -

Buy

69.12%

Hold

9.65%

Sell

21.23%

69.12%

1088 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

59%

Sell Order Quantity

41%

Bid Price

Qty

6600.50

50

6600.00

310

6600.00

31

6599.00

27

6598.00

34

Bid Total

34092

Bid Price

Qty

6604.00

103

6604.00

37

6605.00

30

6606.00

64

6606.00

73

Bid Total

23652

Option Chain

Analyzes market sentiment, predicts Divi's Laboratories Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Divi's Lab - Copy of Newspaper Publication

    8 Nov 2025, 12:30PM Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

  • Divi's Lab - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Nov 2025, 6:09PM Divi's Laboratories Limited has informed the Exchange about Link of Recording

  • Divi's Lab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 Nov 2025, 6:08PM Submission of audio link of Q2FY26 earnings call held on November 07, 2025.

  • Divi's Lab Q2 net profit up 34.36% at Rs 696.00 cr

    7 Nov 2025, 4:32PM The company reported standalone net profit of Rs 696.00 crore for the quarter ended September 30, 2025 as compared to Rs 518.00 crore in the same peri

  • Divi's Lab - Appointment

    7 Nov 2025, 12:12PM Divi's Laboratories Limited has informed the Exchange regarding Appointment of Mr Nimmagadda Venkata Anirudh as President (Nutraceuticals) and Senior

  • Divi's Lab - Announcement under Regulation 30 (LODR)-Change in Management

    7 Nov 2025, 12:12PM As per enclosed letter.

  • Divi's Lab - Announcement under Regulation 30 (LODR)-Change in Management

    7 Nov 2025, 12:11PM As per enclosed letter.

  • Divi's Lab - Outcome of Board Meeting

    7 Nov 2025, 12:07PM Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Divi's Lab - Board Meeting Outcome for Outcome Of Board Meeting

    7 Nov 2025, 12:03PM As per enclosed letter.

  • Divi's Lab - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Oct 2025, 1:08PM Divi's Laboratories Limited has informed the Exchange about Schedule of Q2FY2026 earnings conference call.

  • Divi's Lab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Oct 2025, 1:28PM Schedule of earnings conference call for Q2FY26

  • Divi's Lab - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half

    27 Oct 2025, 5:12PM Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consider a

  • Divi's Lab - Copy of Newspaper Publication

    14 Oct 2025, 12:01PM Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

  • Divi's Lab has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    11 Oct 2025, 10:21PM As of September 2025, 51.88% is owned by Indian Promoters and 48.11% by Public. <p align=justify> Institutional holds 39.16% (Insurance Companies 5.11

  • Divi's Lab - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Oct 2025, 11:52AM Divi's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Divi's Lab - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Oct 2025, 11:42AM Certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018

  • Divi's Lab - Trading Window

    30 Sep 2025, 8:50AM Divi's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Divis Laboratories

    21 Apr 2025 , 10:00AM Divi’s Laboratories: Company signed a long-term manufacturing and supply deal with a global pharmaceutical firm. Plans to invest Rs 650–700 crore to expand capacity. Positive

  • Divi's Laboratories

    25 Apr 2024 , 1:45PM The Company is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between ₹650 crores to ₹700 crores, to be funded from internal accruals. The proposed facility is expected to be operational around January, 2027. Due to the confidentiality agreement signed with the customer, the Company is not permitted to disclose any further quantitative details. Positive.

  • Divi's Labs to expand capacity with an investment of up to Rs. 700 cr

    25 Apr 2024 , 11:25AM Divi's Laboratories is in the process of entering into a long-term supply agreement

  • Stock Update: Divi’s Laboratories

    16 Feb 2024 , 11:46AM Stock Update: Divi’s Laboratories - Q3 misses mark, margins to stay off peak

  • Divis Laboratories

    17 Nov 2023 , 10:31AM The company received order pertaining to recovery of refund of IGST granted under Rule 96 of CGST Rules, 2017 alleged to have been claimed erroneously in terms of the provisions of the GST Act, 2017 (‘GST Law’). Demand raised: IGST of Rs. 82,04,24,880/- along with applicable interest and penalty of Rs. 82,04,24,880/- being 100% of the tax amount (IGST). (Negative)

  • Stock update Divis Laboratories

    8 Nov 2023 , 12:24PM Stock update Divis Laboratories Ltd – Result update - Headwinds mar Q2, long-term opportunity intact

  • Divi’s Laboratories Q3FY23 Results

    3 Feb 2023 , 2:21PM Divi’s Laboratories Q3FY23 Results-: Strong underperformance

  • Stock Update – Divis Laboratories Annual Report Review

    29 Aug 2022 , 11:13AM Stock Update – Divis Laboratories Annual Report Review: Near term uncertainties apparent; long-term levers intact

  • Divis Labs Q1FY23

    12 Aug 2022 , 2:06PM Divis Labs Q1FY23: Operating performance miss estimates; lower tax leads to double digit PAT growth

  • Stock Update – Divis Laboratories Limited Q4FY22

    24 May 2022 , 1:32PM Stock Update – Divis Laboratories Limited Q4FY22: Q4 exceeds hopes in challenging times

  • Stock Update – Divis Laboratories

    10 Mar 2022 , 12:11PM Stock Update – Divis Laboratories Limited: Price correction provides a good opportunity

  • Divis Labs Q3FY22: Impressive performance

    11 Feb 2022 , 1:10PM Divis Labs Q3FY22: Impressive performance; Results ahead of estimates

  • Divis Laboratories

    24 Dec 2021 , 11:21AM The USFDA has issued an Emergency Use Authorization (EUA) to MSD's Covid-19 antiviral oral medication – Molnupiravir, which is administered as four 200 milligram capsules taken orally every 12 hours for five days. The drug is not approved for usage in patients younger than 18 years. Divis Laboratories has entered in to an agreement with Merck Sharpe and Dohme to supply API for Molnupiravir and hence the EUA could have a positive rub off effect on Divis.

  • Stock Update: Divis Labs - Q2FY22 results review

    9 Nov 2021 , 10:54AM Stock Update: Divis Labs - Q2FY22 results review: Q2 growth moderates; long term levers intact

  • Divis Q2FY2022 result

    8 Nov 2021 , 10:52AM Divis Q2FY2022 result: Strong quarter; Operating performance in-line with estimates

  • Divis Labs to gain from licensing deal for COVID drug

    28 Oct 2021 , 3:16PM Divis Laboratories has an agreement to supply API for Molnupiravir to MSD’s licensing partners in India

  • Divis Laboratories Limited: Q1FY22 Result Update

    9 Aug 2021 , 12:14PM Divis Laboratories Limited: Q1FY22 Result Update - Strong quarter; Encouraging growth prospects

  • Divis Laboratories: Q4FY2021 Result Update

    31 May 2021 , 8:31AM Divis Laboratories: Q4FY2021 Result Update – Strong Quarter; Robust growth outlook

  • Divis Laboratories

    26 May 2021 , 2:22PM Divis Labs: The company would be supplying API for Molnupiravor to MSD India’s (wholly owned subsidiary of Merck Sharp & Dohme) voluntary licensing partners in India. Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed COVID-19. Given the surge in the Covid cases in India the demand for Monupiravir could be high, if the drug gets an approval; hence positive

  • Divis Laboratories Limited: Stock Update

    24 Mar 2021 , 9:16AM Divis Laboratories Limited: Stock Update - Sturdy Growth prospects

  • Divis Laboratories Limited: Stock Update

    7 Dec 2020 , 11:56AM Divis Laboratories Limited: Stock Update - Adding muscle to race on the growth path

  • Divis Laboratories

    2 Dec 2020 , 10:49AM The company has earmarked Rs 1,500 crore to set up a new manufacturing facility in Andhra Pradesh – East Godavari district. The work on the manufacturing plant would commence from December 7, 2020. The funding of the said plant would be done through internal accruals in a phased manner. The operations are likely to commence within 12 to 18 months for the first phase of the project. The capacity expansion is positive for the company as it provides visibility on the revenues growth going ahead.

  • Divis Laboratories

    14 Sep 2020 , 3:41PM Divi’s Labs: Following are the key points from the Chairman and Managing Directors Speech at the AGM:

  • Divis Laboratories

    10 Aug 2020 , 11:42AM Divis Laboratories – Q1FY2021 Result Update - On the cusp of a new leap

  • Divis Laboratories

    20 Jul 2020 , 10:06AM the company’s CFO Mr Kishor Babu, is proceeding on leave for a period of 3 months effective from 18 July, 2020, to resolve the allegations of Insider Trading against him in SEBI' s Impounding Order cum Show cause notice. We view this development as positive move from Divis management.

  • Divis Laboratories

    2 Jul 2020 , 9:09AM SEBI has issued an order against CFO of Divis Laboratories in connection with an insider trading case pertaining to the period July 07 to July 10, 2017. This is unlikely to have any material impact on the performance on the stock. We believe this to be sentimentally negative development

  • Divis Laboratories

    9 Jun 2020 , 11:10AM Divis Laboratories: Q4FY20 result update - Best placed to ride Covid crisis

  • Divis Laboratories

    8 Jun 2020 , 10:26AM Divis Q4FY2020 results: Weak operating performance; tax reversal leads to largely in-line PAT

  • Divis Lab commences commercial production

    9 Mar 2020 , 11:16AM Commencement of commercial production from DCV-SEZ Unit

  • Divis Laboratories

    24 Feb 2020 , 11:37AM Divis Laboratories Limited: Stock Update - Well Placed to capitalise on industry tailwinds

  • Divis Laboratories

    7 Feb 2020 , 1:21PM Divis Laboratories: Q3FY2020 Result update – Long term growth levers intact

  • Divis Q3FY2020 result

    6 Feb 2020 , 11:32AM Divis Q3FY2020 result: Weak operating performance leads to PAT miss

  • Divis Laboratories completes USFDA inspection with zero observations

    1 Feb 2020 , 10:29AM USFDA inspection of Unit-II at Village Chippada, Andhra Pradesh

  • Divis Laboratories

    1 Feb 2020 , 9:49AM The company’s unit II at Andhra Pradesh was inspected by the US FDA between 27 Jan to 31 Jan 2020. The inspection was concluded with no observations. Positive

  • Divis Laboratories

    29 Jan 2020 , 10:16AM Cornavirus in China is likely to threaten the sourcing of API’s; Indian API makers like Divis’s Labs is likely to benefit from this – Positive

  • Divis Laboratories

    6 Nov 2019 , 10:46AM Divis Q2FY2020 result: Broadly in –line quarter, gross margins disappoints

  • Divis Q4 number below estimates

    27 May 2019 , 10:32AM Divis numbers below our estimates. Revenue reported growth of 15.5% to Rs 1256.4 cr; profit grew by 10.6% to Rs 289.3 crore. Post an interaction with management we shall review our earnings estimate and come out with detailed note. We currently have buy reco on the stock.

  • Divi’s Lab reports strong Q3FY2019 numbers

    4 Feb 2019 , 12:07PM Divi's Laboratories sales revenue at Rs. 1342.9 crore

  • Divis Lab to be added in MSCI Global Standard Index

    30 Nov 2018 , 11:37AM Divis Lab stock to be added in MSCI Global Standard Index India from November 30th 2018 – Positive read thru

  • Divi's Laboratories posts strong Q2 performance

    29 Oct 2018 , 10:15AM Divis Q2FY2019: Strong performance; beats estimates

  • Divis Laboratories up 2% in weak market

    17 Sep 2018 , 10:07AM Divi's Labs rises over 2% to Rs1362.35, after Phillip Capital upgrades their rating

  • Divis: Q1FY2019 performance in-line with expectation

    7 Aug 2018 , 12:05PM Divis: Business normalcy resumes as USFDA woes end; Maintain Buy

  • Divi's Laboratories Q1FY2019 numbers in line

    6 Aug 2018 , 10:47AM Divi's Labs profit rises by 50.8% to Rs351.9 cr for the Quarter ended June 30, 2018 (YoY)

  • Divi's gains after USFDA inspection with zero observations

    17 May 2018 , 11:23AM Divi's Labs announces its unit at Choutuppal in Telangana has undergone successful inspection by the USFDA from May 14-16, without any observations

  • Divi's Lab clears USFDA inspection with zero observations

    17 May 2018 , 10:13AM Positive for Divi's Lab.

  • Divi’s Unit inspection undertaken by Health Canada

    16 Nov 2017 , 8:52AM Divi's Lab's stock to remain in focus as Health Canada begins inspection of Divi’s Unit – 2 at Vizag

  • Divis lab's Vizag Unit- 2 free from import alert

    15 Nov 2017 , 9:17AM Positive news for Divis lab as USFDA lifts import alert 66-40 from Vizag Unit- 2

  • Divis Lab's import alert and warning letter issues resolved

    3 Nov 2017 , 11:01AM Successful resolution of import alert and warning letter in a short span of time restores the confidence in the company and its management.

  • Divi's spurts as USFDA to lift import alert on Visakhapatnam unit

    2 Nov 2017 , 2:16PM Divi's Lab surges over 21% at Rs1117, after US drug regulator will be lifting its import alert issued to the company's unit-II at Visakhapatnam

  • Divis Lab's Q2 results disappoint; H2 expected to be better

    2 Nov 2017 , 10:22AM Disappointing performance continued on account of elongated time to establish protocols and procedures required to export the exempted products and absence of revenues from non-exempted products.

  • USFDA to lift Import Alert from Divi’s Unit- 2 in Vishakhapatnam

    2 Nov 2017 , 9:29AM Positive news for Divi’s as USFDA to lift Import Alert (Clause 66-40) from Unit- 2 in Vishakhapatnam.

  • Divis continues to report another weak quarter

    1 Nov 2017 , 4:21PM Performance continues to be impacted due to Import Alert issued by the USFDA and time required for setting up protocols and procedures for release of export shipments.

  • Divis Lab: Stock Update

    3 Oct 2017 , 10:17AM Continuation of procedural lapses could delay resolution; maintain Hold. Read details below:

  • Divis' labs unit-2 at Vizag to see early resolution of import alert

    27 Sep 2017 , 9:12AM As per media reports, Lifting or early resolution of import alert at Divis’ labs unit-2 at Vizag – Negative for Divis

  • Divis Lab: Resolution of regulatory hurdles underway

    21 Sep 2017 , 11:17AM As per the management clarification, all previous observations have been completely resolved. Maintain Hold with PT of Rs 1040.

  • Divi's Lab gains on successful USFDA inspection

    20 Sep 2017 , 1:31PM Divi's Lab rises over 7% to Rs925.9, after its unit 2 received six observations from USFDA but all its previous observations are resolved

  • Divi's Lab's unit 2 at Vizag to undergo USFDA re-inspection

    12 Sep 2017 , 12:46PM As per media reports, Divi's Lab's unit -2 at Vizag is undergoing USFDA re-inspection – Stock to remain in focus until outcome of the audit.

  • Divi's Lab's unit 2 at Vizag to undergo USFDA re-inspection

    12 Sep 2017 , 12:45PM As per media reports, Divi's Lab’s unit -2 at Vizag is undergoing USFDA re-inspection – Stock to remain in focus until outcome of the audit.

  • Divis lab completes remediation of Unit-2 in Vizag

    8 Sep 2017 , 10:14AM As per media reports, Divis lab has completed remediation of Unit-2 in Vizag and has re-invited USFDA for inspection – Stock to remain in focus.

  • Divi's Lab: Import Alert remains key overhang

    6 Jun 2017 , 2:45PM Divis Laboratories Q4FY2017 net sales declined by 2.6% YoY to Rs1,067 crore
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Divi's Laboratories Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 14897 13484 12705.42 11691.35 9271.92
Liabilities 14897 13484 12705.42 11691.35 9271.92
Equity 53 53 53.09 53.09 53.09
Gross Profit 2979 2174 2347.68 3876.46 2820.68
Net Profit 2209 1576 1808.15 2948.54 1954.72
Cash From Operating Activities 1650 1266 2447.95 1910.16 1947.05
NPM(%) 24.01 20.56 23.71 33.2 28.75
Revenue 9198 7665 7625.3 8879.82 6798.61
Expenses 6219 5491 5277.62 5003.36 3977.93
ROE(%) 14.75 10.52 12.07 19.69 13.05

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
25 Jul 2025 30 1500 0.46 6580
02 Aug 2024 30 1500 0.46 4255.25
11 Aug 2023 30 1500 0.46 3265
11 Aug 2022 30 1500 0.46 3897.9
17 Aug 2021 20 1000 0.46 4194
25 Feb 2020 16 800 0.46 2121.8
14 Aug 2019 16 800 0.46 1593.45
31 Aug 2018 10 500 0.46 1092.15
15 Sep 2017 10 500 0.46 545.3
17 Mar 2016 10 500 0.46 970.45
06 Aug 2015 20 1000 0.46 1815.8
31 Jul 2014 20 1000 0.46 1242.65
25 Jul 2013 15 750 0.46 1082.2
16 Jun 2011 10 500 0.46 727.4
02 Jul 2010 6 300 0.46 719.45
15 Jun 2009 6 300 0.46 1189
26 Jun 2008 4 200 0.46 1453.15
23 Mar 2007 10 100 0.46 2833.25
11 Aug 2005 8 80 0.46 1061.4
29 Jul 2004 8 80 0.46 1291.7
11 Aug 2003 6 60 0.46 331.1

Peers

Other companies within the same industry or sector that are comparable to Divi's Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 838.00 -4.87 75.97 3720.70 301.39 0.60
Lotus Eye Hospital and Institute Ltd 114.51 -2.72 369.39 13557.73 3.55 0.00
Vaishali Pharma Ltd 9.72 0.41 324.00 85052.16 3.13 0.00
Astec Lifesciences Ltd 625.00 2.03 0.00 12785.25 -604.77 0.00

Company Info

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA 2017 - Divi's reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh -Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad. 2018 -Divi's Laboratories climbs nearly 2% on rating upgrade. -Expanded the product portfolio to over 30 products. -Divi's Laboratories Market capital of $5B Reached. 2019 -Divi's Laboratories approves Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II. -7th USFDA inspection in Unit 2. 2020 - Commissioning new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II. -Divi's Lab - US-FDA Inspection Of Unit -II At Village Chippada, Andhra Pradesh. -Divi's Lab - Intimation Of Commencement Of Commercial Production From DCV-SEZ Unit. -Divi's Lab - Commencement Of Construction Of Divi's Laboratories Unit-III Facility Near Kakinada 2021 -Ground Breaking of Manufacturing plant in Kakinada 2022 -Divi's Laboratories received EHS excellence Award. -Divi's reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad. 2024 -Divi's global presence in supplying APIs to more than 100 countries,

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA 2017 - Divi's reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh -Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad. 2018 -Divi's Laboratories climbs nearly 2% on rating upgrade. -Expanded the product portfolio to over 30 products. -Divi's Laboratories Market capital of $5B Reached. 2019 -Divi's Laboratories approves Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II. -7th USFDA inspection in Unit 2. 2020 - Commissioning new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II. -Divi's Lab - US-FDA Inspection Of Unit -II At Village Chippada, Andhra Pradesh. -Divi's Lab - Intimation Of Commencement Of Commercial Production From DCV-SEZ Unit. -Divi's Lab - Commencement Of Construction Of Divi's Laboratories Unit-III Facility Near Kakinada 2021 -Ground Breaking of Manufacturing plant in Kakinada 2022 -Divi's Laboratories received EHS excellence Award. -Divi's reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad. 2024 -Divi's global presence in supplying APIs to more than 100 countries,

Read More

Parent Organisation

Divi's Laboratories Ltd.

Founded

12/10/1990

Managing Director

Dr.Murali K Divi

NSE Symbol

DIVISLABEQ

FAQ

The current price of Divi's Laboratories Ltd is ₹ 6564.50.

The 52-week high for Divi's Laboratories Ltd is ₹ 6576.50 and the 52-week low is ₹ 6473.00.

The market capitalization of Divi's Laboratories Ltd is currently ₹ 174266.85. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Divi's Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Divi's Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Divi's Laboratories Ltd shares.

The CEO of Divi's Laboratories Ltd is Dr.Murali K Divi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT